- Case report
- Open Access
Acute myocardial infarction, associated with the use of a synthetic adamantyl-cannabinoid: a case report
BMC Pharmacology and Toxicology volume 17, Article number: 2 (2016)
“Legal highs” are novel psychoactive substances that have evaded statutory control. Synthetic cannabinoid compounds with adamantane moieties have recently been identified, which have high potency at target receptors and are undetectable on conventional toxicology testing. However, little is known about any harmful effects, and their potential to cause serious ill health. We describe a case of myocardial infarction following the use of this class of drug.
We report the case of a 39-year-old man admitted after an out-of-hospital cardiac arrest, in whom ECG and elevated cardiac enzymes confirmed ST-elevation myocardial infarction. Normal coronary perfusion was restored after thrombectomy and coronary artery stenting. In the hours preceding his admission, the patient is known to have consumed the legal high product “Black Mamba”. Subsequent urine testing confirmed the presence of an adamantyl-group synthetic cannabinoid, whilst cannabis, cocaine, amphetamines and other drugs of abuse were not detected.
The use of legal highs is being increasingly recognised, but the chemical compositions and physiological effects of these drugs are poorly characterised and are continually changing. Synthetic cannabinoids, rarely identified on toxicological testing, can be linked to serious adverse cardiovascular events. This case highlights the importance of testing for novel psychoactive compounds, and recognising their potential to cause life-threatening conditions.
Recreational use of cannabis dates back centuries. More recently, herbal mixtures have emerged that produce similar effects to cannabis when smoked. Sold under various names, including Spice, K2 and Black Mamba, these preparations can contain synthetically-derived compounds with high affinity for endogenous cannabinoid CB receptors .
Novel psychoactive compounds are constantly being developed and later prohibited in a cat-and-mouse game between the legal high manufacturers and governments. Synthetic cannabinoids represent an evolving drug class that are sold openly (although frequently labelled “not for human consumption”), produce stimulant effects in those that smoke them, and are often undetectable on routine toxicology testing.
However, because of their unregulated development, synthetic cannabinoids can have potentially serious side effects, putting those that use them at an unknown risk of harm. Here, we report a case of myocardial infarction and cardiac arrest associated with a new class of adamantyl-group synthetic cannabinoid, confirmed by urine drug testing.
A 39-year-old man presented to the emergency department after a witnessed collapse and cardiac arrest. He was Caucasian, with a body mass index of 28.8 kg/m2, and a smoker. His past medical history consisted of depression and a single episode of deep venous thrombosis of the calf. There was no personal or family history of cardiac disease, he was neither diabetic nor hypertensive, and had a normal serum cholesterol level (2.5 mmol/l). Although he initially denied illicit drug use, a third party confirmed he had smoked “Black Mamba” within three hours of the onset of his symptoms.
He initially reported left-sided chest pain, associated with dizziness and dyspnoea. Minutes later, the patient collapsed, cardiac output became undetectable, and cardio-pulmonary resuscitation was commenced. Out-of-hospital cardiac monitoring revealed ventricular fibrillation, and spontaneous circulation was restored after delivery of four direct current shocks. During transfer to hospital, ECG demonstrated ST elevation in antero-lateral leads (Fig. 1), and the patient was admitted directly for cardiac catheterisation. The serum Troponin-T level was recorded at 4398 ng/L (normal range <14 ng/L on high-sensitivity Troponin-T), confirming the diagnosis of myocardial infarction.
Coronary angiography revealed an ostial occlusion to the left anterior descending artery, which was treated by thrombectomy. There was some residual stenosis, which could have represented mild coronary artery disease or persistent vasospasm. As it did not respond to nitrate treatment, a Xience drug-eluting stent (Abbott) was placed. The left circumflex and right coronary arteries were angiographically normal, and there were only mild irregularities in an intermediate artery. The patient experienced no further symptoms of cardiac ischemia, and the ST elevation resolved after percutaneous coronary intervention. He was discharged with anti-platelet therapy (ticagrelor 90 mg twice daily for one year, aspirin 75 mg daily for life) and secondary prevention for coronary artery disease (atorvastatin 80 mg daily, bisoprolol 2.5 mg daily and perindopril 2 mg daily).
Urine toxicology tested positive for opiates and benzodiazepines (both given on admission to hospital), and also for adamantyl-group synthetic cannabinoids. Other drugs of abuse were not detected, including cannabis, cocaine and amphetamines. Drugs were assayed by liquid tandem mass spectrometry (UPLC-MS/MS), and confirmed by time-of-flight mass spectroscopy.
In England and Wales, cannabis is consistently the most frequently used illegal drug . Although relatively uncommon, cannabis use is associated with a number of serious cardiovascular conditions, including myocardial infarction and stroke , with cases of both coronary artery thrombosis and vasospasm reported [4, 5]. Synthetic cannabinoid use has been associated with admission to hospital for a range of symptoms, including anxiety, seizure, vomiting, and chest pain [6, 7]. ECG changes are rarely seen after synthetic cannabinoid use, but possible mechanisms for increasing the risk of myocardial infarction include tachycardia, hypertension, and metabolic disturbances such at hypokalaemia . Although most toxicities are classed as minor or moderate , more synthetic cannabinoid users seek medical attention than would be expected for cannabis . The increased risk of adverse reaction to synthetic cannabinoid, compared to cannabis, could be due to higher potency at CB receptors, or to uncharacterised interactions with other endogenous targets. Moreover, with the diversity of molecular moieties seen on synthetic cannabinoids, it is possible that the different classes have distinct target profiles.
Synthetic cannabinoid use has previously been associated with acute myocardial infarction, in both adults and children [11–14]. However, in many of these reports, the self-reported use of synthetic cannabinoid products is not confirmed by biochemical testing, and some patients also tested positive for cannabis. Here, we describe a patient whose reported drug use was confirmed by urine toxicology testing, which also ruled out use of cannabis and other drugs of abuse. Animal studies have recorded physiological effects of adamantyl-cannabinoids from one to six hours after administration, and a human study found metabolite excretion peaked five to seven hours after self-administration and was still detectable up to 160 hours later [15–17]. Although inhaling synthetic cannabinoids results in unpredictable doses , the details of our case are consistent with the known pharmacological properties of these substances. Coronary angiography showed mild residual irregularities after thrombectomy, and given a personal history of deep venous thrombosis, it is possible that this patient was particularly vulnerable to a cardiovascular event. However, his 10-year QRISK2 score (ClinRisk Ltd.) was 2.6 %, therefore the major contributor to this event is most likely the consumption of the adamantyl-cannabinoid in the hours before his presentation.
We report a case of acute myocardial infarction associated with use of an adamantyl-cannabinoid. Adamantane moieties have recently been found in synthetic cannabinoid compounds, and they produce potent CB receptor ligands . The Clinical Biochemistry Department of our NHS Trust, closely linked to the UK National Poisons Information Service, continually screens samples received for toxicology testing, as well as legal high samples seized by UK Trading Standards and from prisons. Our testing has found that adamantyl-cannabinoids are currently the most popular class of synthetic cannabinoid on sale in the UK, particularly AKB-48, 5 F-AKB-48 and STS-135. Our drugs of abuse screen, carried out on urine samples, yields a positive result for adamantyl-cannabinoids if any of these compounds are detected .
Most of the previous reports of acute myocardial infarction were associated with the JWH class of synthetic cannabinoid. However, the trend in Europe has been away from this older class of drug, likely in response to its scheduling as illegal, towards more potent compounds . Consistent with this, our laboratory now rarely detects JWH-class synthetic cannabinoids.
Importantly, the street name of the legal high does not necessarily indicate which psychoactive compound is present. A recent outbreak of neurotoxicity and cardiotoxicity in the US was attributed to a synthetic cannabinoid known locally as “Black Mamba” . However, the compound identified from these patients is chemically distinct from the “Black Mamba” detected in our patient, as it lacks the characteristic adamantane moiety. It is noteworthy that the adamantyl-cannabinoid AKB-48 has been scheduled as illegal in the US , whilst it currently remains unscheduled in the UK. This reflects the ongoing evolution of legal highs, driven by consumer demand for the drugs and statutory bodies criminalising their use.
The legal high market is buoyant and rapidly evolving. Whilst many illegal and controlled pharmaceutical drugs can be identified with toxicology testing, novel psychoactive substances are often undetectable on routine testing. Their prevalence is therefore likely to be under-reported, and their precise chemical composition unknown. However, use of synthetic cannabinoids exposes people to the risk of serious harm, including acute myocardial infarction. It is important to identify when patients have consumed psychoactive substances, both to manage any complications that arise, and also to inform the wider public health debate.
Written informed consent was obtained from the patient for publication of this case report and any accompanying images. A copy of the written consent is available for review by the Editor of this journal.
National health service
European Monitoring Centre for Drugs and Drug Addiction. Understanding the “Spice” phenomenon. 2009.
Home Office. Drug Misuse: Findings from the 2013/14 Crime Survey for England and Wales. UK: Her Majesty's Stationery Office (HMSO); 2014.
Thomas G, Kloner RA, Rezkalla S. Adverse cardiovascular, cerebrovascular, and peripheral vascular effects of marijuana inhalation: what cardiologists need to know. Am J Cardiol. 2014;113(1):187–90.
Tatli E, Yilmaztepe M, Altun G, Altun A. Cannabis-induced coronary artery thrombosis and acute anterior myocardial infarction in a young man. Int J Cardiol. 2007;120(3):420–2.
Gunawardena MDVM, Rajapakse S, Herath J, Amarasena N. Myocardial infarction following cannabis induced coronary vasospasm. BMJ Case Rep. 2014;bcr2014207020.
Hoyte CO, Jacob J, Monte AA, Al-Jumaan M, Bronstein AC, Heard KJ. A characterization of synthetic cannabinoid exposures reported to the National Poison Data System in 2010. Ann Emerg Med. 2012;60(4):435–8.
Harris CR, Brown A. Synthetic cannabinoid intoxication: a case series and review. J Emerg Med. 2013;44(2):360–6.
Castaneto MS, Gorelick DA, Desrosiers NA, Hartman RL, Pirard S, Huestis MA. Synthetic cannabinoids: epidemiology, pharmacodynamics, and clinical implications. Drug Alcohol Depend. 2014;144:12–41.
Hermanns-Clausen M, Kneisel S, Szabo B, Auwärter V. Acute toxicity due to the confirmed consumption of synthetic cannabinoids: clinical and laboratory findings. Addiction. 2013;108(3):534–44.
Winstock AR, Barratt MJ. The 12-month prevalence and nature of adverse experiences resulting in emergency medical presentations associated with the use of synthetic cannabinoid products. Hum Psychopharmacol. 2013;28(4):390–3.
Tse R, Kodur S, Squires B, Collins N. Sudden cardiac death complicating acute myocardial infarction following synthetic cannabinoid use. Intern Med J. 2014;44(9):934–6.
Ibrahim S, Al-Saffar F, Wannenburg T. A Unique Case of Cardiac Arrest following K2 Abuse. Case Reports Cardiol. 2014;2014:120607.
Mir A, Obafemi A, Young A, Kane C. Myocardial infarction associated with use of the synthetic cannabinoid K2. Pediatrics. 2011;128(6):e1622–7.
McKeever RG, Vearrier D, Jacobs D, LaSala G, Okaneku J, Greenberg MI. K2-Not the Spice of Life; Synthetic Cannabinoids and ST Elevation Myocardial Infarction: A Case Report. J Med Toxicol. 2014;11(1):129–31.
Banister SD, Wilkinson SM, Longworth M, Stuart J, Apetz N, English K, et al. The synthesis and pharmacological evaluation of adamantane-derived indoles: cannabimimetic drugs of abuse. ACS Chem Neurosci. 2013;4(7):1081–92.
Banister SD, Stuart J, Kevin RC, Edington A, Longworth M, Wilkinson SM, et al. Effects of bioisosteric fluorine in synthetic cannabinoid designer drugs JWH-018, AM-2201, UR-144, XLR-11, PB-22, 5 F-PB-22, APICA, and STS-135. ACS Chem Neurosci. 2015;6(8):1445–58.
Grigoryev A, Kavanagh P, Melnik A. The detection of the urinary metabolites of 3-[(adamantan-1-yl)carbonyl]-1-pentylindole (AB-001), a novel cannabimimetic, by gas chromatography-mass spectrometry. Drug Test Anal. 2012;4(6):519–24.
Lu D, Meng Z, Thakur GA, Fan P, Steed J, Tartal CL, et al. Adamantyl cannabinoids: a novel class of cannabinergic ligands. J Med Chem. 2005;48(14):4576–85.
Ford LT, Berg JD. 1-adamantylamine a simple urine marker for screening for third generation adamantyl-type synthetic cannabinoids by UPLC-MS/MS. Ann Clin Biochem. 2015 (in press).
Monte AA, Bronstein AC, Cao DJ, Heard KJ, Hoppe JA, Hoyte CO, et al. An outbreak of exposure to a novel synthetic cannabinoid. N Engl J Med. 2014;370(4):389–90.
DEA. Drug Enforcement Administration. Department of Justice. Schedules of Controlled Substances: Temporary Placement of Three Synthetic Cannabinoids Into Schedule I. Fed Regist. 2013;78(95):28735–9.
We thank Dr Sally Bradberry for comments on the manuscript. All authors are employed by Sandwell and West Birmingham Hospitals NHS Trust, part of the UK National Health Service. No additional funding was received during the preparation of this manuscript.
The authors declare that they have no competing interests.
GM contributed to, and JK was responsible for, the care of the patient. LF carried out the toxicological testing. GM drafted the manuscript. All authors read, contributed to, and approved the final manuscript.
Rights and permissions
Open Access This article is distributed under the terms of the Creative Commons Attribution 4.0 International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.
About this article
Cite this article
McIlroy, G., Ford, L. & Khan, J.M. Acute myocardial infarction, associated with the use of a synthetic adamantyl-cannabinoid: a case report. BMC Pharmacol Toxicol 17, 2 (2016). https://doi.org/10.1186/s40360-016-0045-1
- Myocardial infarction
- Novel psychoactive compounds
- Synthetic cannabinoid